Patents by Inventor Krishna Jawaharlal FISHER

Krishna Jawaharlal FISHER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRANS-SPLICING MOLECULES
    Publication number: 20240318186
    Abstract: The present invention features nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs)) capable of correcting one or more mutations in the ABCA4 gene or the CEP290 gene. Such molecules are useful in the treatment of disorders associated with mutations in ABCA4, such as Stargardt Disease (e.g., Stargardt Disease 1) and disorders associated with a mutation in CEP290, such as Leber congenital amourosis 10 (LCA 10). Also provided by the invention described herein are methods of using the nucleic acid trans-splicing molecules for correcting mutations in ABCA4 and CEP290 and for treating disorders associated with mutations in ABCA4 and CEP290, such as Stargardt Disease and LCA 10.
    Type: Application
    Filed: May 24, 2024
    Publication date: September 26, 2024
    Inventors: Philip R. JOHNSON, Bruce C. Schnepp, Jean Bennett, Scott J. Dooley, Krishna Jawaharlal Fisher, Junwei Sun
  • Trans-splicing molecules
    Patent number: 11993776
    Abstract: The present invention features nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs)) capable of correcting one or more mutations in the ABCA4 gene or the CEP290 gene. Such molecules are useful in the treatment of disorders associated with mutations in ABCA4, such as Stargardt Disease (e.g., Stargardt Disease 1) and disorders associated with a mutation in CEP290, such as Leber congenital amourosis 10 (LCA 10). Also provided by the invention described herein are methods of using the nucleic acid trans-splicing molecules for correcting mutations in ABCA4 and CEP290 and for treating disorders associated with mutations in ABCA4 and CEP290, such as Stargardt Disease and LCA 10.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: May 28, 2024
    Assignees: Ascidian Therapeutics, Inc., The Trustees of the University of Pennsylvania
    Inventors: Philip R. Johnson, Bruce C. Schnepp, Jean Bennett, Scott J. Dooley, Krishna Jawaharlal Fisher, Junwei Sun
  • TRANS-SPLICING MOLECULES
    Publication number: 20210155938
    Abstract: The present invention features nucleic acid trans-splicing molecules (e.g., pre-mRNA trans-splicing molecules (RTMs)) capable of correcting one or more mutations in the ABCA4 gene or the CEP290 gene. Such molecules are useful in the treatment of disorders associated with mutations in ABCA4, such as Stargardt Disease (e.g., Stargardt Disease 1) and disorders associated with a mutation in CEP290, such as Leber congenital amourosis 10 (LCA 10). Also provided by the invention described herein are methods of using the nucleic acid trans-splicing molecules for correcting mutations in ABCA4 and CEP290 and for treating disorders associated with mutations in ABCA4 and CEP290, such as Stargardt Disease and LCA 10.
    Type: Application
    Filed: April 17, 2019
    Publication date: May 27, 2021
    Inventors: Philip R. JOHNSON, Bruce C. SCHNEPP, Jean BENNETT, Scott J. DOOLEY, Krishna Jawaharlal FISHER, Junwei SUN